Ensysce Biosciences, Inc. (ENSC)

Nasdaq: ENSC · Pharmaceutical Preparations · La Jolla, CA · filing with the SEC since 2017

Full chart Alerts Compare

Grade3.8

◀ Past 1.8● Present 3.5▶ Future 5.2

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Ensysce Biosciences, Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.8/10

◀ Past1.825% of the headline

● Present3.535% of the headline

▶ Future5.240% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.8/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.5/10

Has it survived what it has been through?

15 warning events since 2017; the latest 2026-05-22.

weight 22% of this tense · 5th percentile among 497 sector filers · read for itself

From the record

Ensysce Biosciences, Inc.'s filings since 2017 show 15 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 10 times, the latest 2026-05-22); a warning not to rely on past financial statements (8-K item 4.02, the latest 2021-05-14); an auditor change (8-K item 4.01, 3 times, the latest 2025-06-05); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2021-05-17) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

3.3/10

What has it actually done, year after year?

+5.2% a year over 6 filed years; profitable in 0 of 6.

weight 45% of this tense · 33rd percentile among 323 sector filers · read for its customers

From the record

Ensysce Biosciences, Inc.'s 6 filed years say what it did: revenue went from $4 million in fiscal 2020 to $5 million in fiscal 2025, up 5.2% a year; it rose in 1 of 5 years; the deepest fall was 43% from fiscal 2020 to fiscal 2023; net income was positive in 0 of 6 of those years (its annual reports).

What it rests on

revenue growth over the filed span5.2%bottom 36% of its family
the share of years revenue rosebottom 9% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak43.3%top 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

0.7/10

How has it treated the people who own it?

SI estimate 0.7/10, confidence 35 of 100 (one part).

weight 33% of this tense · 7th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 7% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ensysce Biosciences, Inc.'s shareholder treatment is put at 0.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 7% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.5/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

1.8/10

Is it financially healthy right now?

ROE -317%: lost 317¢ per shareholder dollar. Leverage 57%: owes 57¢ per asset dollar.

weight 45% of this tense · 18th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Ensysce Biosciences, Inc. lost about 317 cents for every dollar of shareholders' money. Leverage: it owed about 57 cents per dollar of assets, and net share issuance: its share count grew 266.6% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 29% of its family
return on equitybottom 8% of its family
the share count against the year beforebottom 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

4.9/10

How strong is its position in its industry?

bottom 49% of 315 in its family; net margin -200.8%.

weight 22% of this tense · 49th percentile among 315 sector filers · read for its customers

From the record

Ensysce Biosciences, Inc.'s standing among 315 graded names in its industry family: revenue of $5 million in fiscal 2025 ranks in the bottom 34% by size; a net margin of -200.8% ranks in the bottom 46%; revenue growth of 26.2% a year over the last 3 filed years ranks in the top 33% (its annual reports).

What it rests on

revenue against the family$5.1Mbottom 34% of its family
net margin-200.8%bottom 46% of its family
three-year revenue growth26.2%top 33% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ensysce Biosciences, Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.2/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

5.8/10

How much room does it have to grow?

top 42% of 273 in its family for room to expand.

weight 33% of this tense · 58th percentile among 273 sector filers · read for itself

From the record

Ensysce Biosciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $4 million against no long-term debt tagged leaves 57.8% of its assets as net cash, top 29% of its family; cash from operations less capital spending is -156.5% of revenue (bottom 45%); research spending of 204.8% of revenue (top 42%) (its annual report).

What it rests on

cash less debt against assets57.8%top 29% of its family
cash from operations less capital spending against revenue-156.5%bottom 45% of its family
research spending against revenue204.8%top 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

4.7/10

What could actually drive growth from here?

bottom 47% of 306 in its family for growth drivers.

weight 45% of this tense · 47th percentile among 306 sector filers · read for its customers

From the record

Ensysce Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 26.2% a year over the last three filed years against 5.2% over all 6, speeding up (top 13% of its family); the newest year grew -2.8% (bottom 34%); research spending grew -19.4% a year (bottom 19%) (its annual reports). Ensysce Biosciences, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+20.9 points a yeartop 13% of its family
the newest year's revenue growth-2.8%bottom 34% of its family
three-year growth of research spending-19.4%bottom 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

5.3/10

Did its newest year beat what its own record pointed to?

top 47% of 233 in its family for expectations against reality.

weight 22% of this tense · 53rd percentile among 233 sector filers · read for its shareholders

From the record

Ensysce Biosciences, Inc.'s newest year against its own record: revenue of $5 million in fiscal 2025 came in 32.3% below the $7 million its prior three years' pace pointed to (bottom 25% of its family); net income of $10 million against a prior three-year average of $14 million (top 41%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 24%) (its annual reports).

What it rests on

revenue against the prior three years' pace-32.3%bottom 25% of its family
net income against the prior three years' average+29%top 41% of its family
net margin against its prior averageup more than 100 pointstop 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ENSC · research, not advice